ArticleInternational journal of fertility & sterility2025
Navigating The CeRNA Axis by Bioinformatics and Experimental Validation: Identification of
Article in International journal of fertility & sterility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial carcinoma (EC) is a significant gynecologic malignancy. Investigating competing endogenous RNA (ceRNA) networks, including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs), offers insights into EC's molecular intricacies and may improve therapeutic and diagnostic strategies. This study focuses on the ceRNA axis, particularly the interactions of lncRNA-miRNA-mRNA-Gene, using TCGA-UCEC database analysis and experimental validation. Materials and Methods: In this case-control study, differentially expressed lncRNAs (DElncRNAs), microRNAs (DEMIs), and genes (DEGs) were identified, highlighting ADIRF-AS1 as a potential target. Validated interactions between ADIRF-AS1, miR-191-5p, and EGR1 were established, with significant ADIRF-AS1/EGR1 correlation. Protein-protein interaction (PPI) analysis identified 21 proteins linked to EGR1, with gene ontology (GO) analysis revealing roles in myeloid cell differentiation. Expression levels of genes, lncRNA, and microRNAs were evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Western blot analysis was applied for protein evaluation. Results: RT-qPCR results showed that the RNA expression levels of ADIRF-AS1 and EGR1 genes in endometrial cancer and hyperplasia samples were significantly lower (P<0.001) than control samples. Also, the expression level of miR-191-5p in endometrial cancer tissues was significantly higher than patients with hyperplasia (P<0.001) and normal samples (P<0.001). Western blot results also showed that the protein level of EGR1 in endometrial cancer samples was significantly lower than control samples (P<0.001). Conclusion: Here, we observed an interaction between lncRNA ADIRF-AS1and hsa-miR-191-5p, and also, ADIRFAS1 downstream effects on EGR1 in EC, that seems may be a suggesting therapeutic and diagnostic targets. Further research could explore its clinical relevance in endometrial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.